Purpose of review Extensive research in murine transplant models over the past two decades has convincingly demonstrated the ability of regulatory dendritic cells (DCregs) to promote long-term allograft survival. We review important considerations regarding the source of therapeutic DCregs (donor or recipient) and their mode of action, in-situ targeting of DCregs, and optimal therapeutic regimens to promote DCreg function.
INTRODUCTION
Dendritic cells have inherent tolerogenic properties that can be harnessed to promote long-term organ allograft survival and reduce transplant recipients' dependence on immunosuppressive drugs. New mechanistic insights have recently been gained into the underlying basis of regulatory dendritic cell (DCreg) therapy and into how in-situ targeting of dendritic cells can be exploited to promote tolerance. Important steps have also been taken to evaluate the safety and efficacy of DCregs in a clinically relevant nonhuman primate (NHP) organ transplant model and to generate clinical grade DCregs that have entered phase I clinical trials.
DONOR-DERIVED VERSUS ANTIGEN-PULSED AUTOLOGOUS REGULATORY DENDRITIC CELL THERAPY IN TRANSPLANTATION
During the 1990s, growing understanding of the role of dendritic cells of myeloid lineage in peripheral T-cell tolerance [1, 2] , together with advances in methods to generate large numbers of dendritic cells in the laboratory, led to the possibility of 'negative vaccination' with DCregs. These cells could be shown to restrain immune responses to cell and organ allografts [3, 4] and to promote long-term transplant survival [5] . Numerous techniques have been described subsequently to generate DCregs from peripheral blood monocytes, CD34 þ hematopoietic progenitors, or bone marrow precursors in human, NHP, and murine models, and ].
Early studies in murine models demonstrated that systemic administration of donor-derived DCregs, 7 days before transplant, decreased the antidonor adaptive immune response and prolonged the survival of solid organ allografts in otherwise untreated recipients (reviewed in [7] [8] [9] 11, 12] ). Prospective clinical use of donor-derived DCregs was restricted to live-donor organ transplantation and could entail the risk of host sensitization. Thus, an important alternative approach, which would allow inclusion of deceased donor transplantation, was to develop negative cellular vaccines based on autologous DCregs loaded with donor antigen. The administration of autologous DCregs pulsed ex vivo with donor antigen in the form of soluble peptides, sonicates, or cell-derived vesicles has proved effective in murine models of organ transplantation (reviewed in [7, 8, 11] ). Moreover, studies in murine models have shown that, when combined with low-dose pharmacologic immunosuppression, donor-derived or recipient-derived DCreg administration leads to long-term graft survival in most cases (reviewed in [7, 11] ). This is significant, as an achievable goal in transplantation is to administer DCregs, not alone, but in combination with reduced doses of immunosuppressive drugs. In a recent review of 13 mouse and rat studies [10] , it was observed that DCregs induced by five different methods prolonged major histocompatibility complex (MHC) -mismatched islet allograft survival to various degrees -and that allopeptidepulsed host dendritic cells performed best. In addition, immunosuppressive drug administration or costimulatory blockade was synergistic with the DCregs and also importantly, multiple injections were not superior to single injection.
The predominant concept underlying negative vaccination with donor DCregs in transplantation is that the injected DCregs migrate to secondary lymphoid organs of the recipient where they downregulate alloimmunity by interacting directly with donor-reactive T cells. However, this idea is based on the impact of DCreg therapies on antidonor responses measured using ex-vivo assays and their influence on allograft survival. Interestingly, there is recent evidence that intravenously administered donor DCregs, or autologous DCregs loaded with donor antigen, exert their immunosuppressive effects, not by themselves, but through host dendritic cells [15, 16] . The injected DCregs are shortlived and are processed by the recipient's quiescent conventional dendritic cells in secondary lymphoid organs. These host dendritic cells in turn promote deletion of donor-specific effector T cells with consequent increases in the relative number of donorspecific CD4 þ forkhead box P3 (Foxp)3 þ regulatory T cells (Tregs) [15] (Fig. 1) . Indeed, transient depletion of host conventional dendritic cells at the time of DCreg administration prevents the beneficial effect of donor or recipient DCreg therapies in mouse cardiac transplantation [16] . Processing of the injected donor-derived DCregs by autologous dendritic cells can also explain why therapy with donor-derived DCreg restrains the rejection of corneal allografts that occurs predominantly via the indirect pathway of allorecognition [17, 18] . Thus, the quiescent/protolerogenic status of host conventional dendritic cells in lymphoid organs that process injected DCregs seems to be key to the success of DCreg therapies. This raises a cautionary note, however, as the quiescent status of host dendritic cells may be altered during end-stage diseases that necessitate organ transplantation. Moreover, in certain mouse models, DCreg therapies have been shown to sensitize recipients via the transfer of donor alloantigen to host antigen-presenting cells (APCs), followed by priming of indirect T cells and the production of IgG alloantibodies [19 & ,20] . Host sensitization has not, however, been Besides, the source of donor antigen and the method for ex-vivo loading of autologous DCregs requires standardization between laboratories. There is evidence, however, that in certain murine models, systemically administered autologous DCregs do not need to be loaded with donor antigen ex vivo to prolong graft survival (reviewed in [9, 22] ). Thus, intravenous injection 1 day before transplant of autologous DCregs (generated in vitro with lowdose granulocyte-macrophage colony-stimulating factor) and not exposed to donor antigen before administration prolongs the survival of heart allografts in rats [23] . Moreover, in combination with the nuclear factor (NF)kb inhibitor LF 15-0195, therapy with nonantigen-pulsed autologous DCregs promotes donor-specific graft acceptance in most recipients [23] . The injected autologous DCregs induce interferon (IFN)-g production by CD4 CD8 double-negative T cells, which accumulate in the spleen of tolerant rats [24] . In this model, expression by autologous DCregs of the cytokine chain Epstein-Barr virus-induced gene 3 (EBI3), a member of the interleukin-12 family, is critical for differentiation of IFN-g þ double-negative T cells [24] . Interestingly, blockade of IFN-g leads to allograft rejection, suggesting that IFN-g plays a suppressive role in this model [24] . Recently, the same group has demonstrated that intravenous administration of nonantigen-pulsed autologous DCregs, 1 day before transplant and in combination with peri-transplant anti-CD3 antibody therapy, prolongs the survival of minor histocompatibility complex-mismatched male skin grafts in female recipients [25 && ]. The beneficial effect of autologous DCreg therapy on graft survival is associated with expansion of a subset of donor-specific CD8
þ CD11c þ Tregs in the graft-draining lymph nodes [25 && ]. Indirect evidence suggests that the injected nonantigen-pulsed autologous DCregs capture donor antigen within the skin grafts before migrating to draining lymph nodes [25 && ] (Fig. 1) . The immunosuppressive effect of these autologous DCregs in vivo is dependent on cross-presentation of internalized donor antigen to CD8 þ T cells [25 && ]. Unlike donor DCregs or autologous DCregs loaded with donor antigen, which need to be injected 7 days before transplant to have maximal effect, nonantigen-pulsed autologous DCregs prolong graft survival when administered peri-transplant. As these nonantigen-pulsed autologous DCregs are not exposed to donor antigen before injection, the potential risk of sensitization against donor antigen is minimized.
In a different context, nonantigen-pulsed autologous DCregs, conditioned in vitro with transforming growth factor (TGF)b and impaired in their ability to produce proinflammatory cytokines, have been used to control T-cell autoimmunity against syngeneic pancreatic islets transplanted in mice with diabetes (nonobese mice with diabetes). In this case, the nonantigen-pulsed autologous DCregs were mixed directly with the islet grafts transplanted under the kidney capsule, which allowed the DCregs to acquire islet-derived antigen locally [26 & ]. Addition of autologous DCregs promoted long-term survival of the islet grafts in most recipients. This occurred despite the presence of a nonpathogenic leukocyte infiltrate in the long-accepted grafts that showed no reduction in the number of CD8 þ T cells or increased presence of FoxP3 þ Tregs [26 & ]. Notably, the immature autologous dendritic cells could delay rejection of islet grafts even when not exposed to TGFb.
IN-SITU TARGETING OF QUIESCENT DENDRITIC CELLS IN SECONDARY LYMPHOID ORGANS TO PROMOTE TRANSPLANT TOLERANCE
Presentation of antigen by immature or semimature conventional dendritic cells in lymphoid organs provides insufficient co-stimulation. This results in antigen-specific downregulation of the T-cell response by means of defective T-cell proliferation, followed by apoptosis, T-cell anergy, and/or generation of adaptive Tregs [27] . Therefore, targeting donor antigen to host conventional dendritic cells in secondary lymphoid organs, without altering the quiescent/inherent protolerogenic status of the APC, constitutes an alternative approach to administration of in-vitro-generated DCregs to promote donor-specific immune suppression. In most such experimental protocols, exogenous antigens are delivered in association with vehicles that bind the recipient's conventional dendritic cells in situ, without altering their quiescent status. These vehicles can be particles (i.e., apoptotic cell vesicles or immature APC-derived exosomes) or recombinant monoclonal Ab (mAb) directed against dendritic cell surface markers.
Following internalization of cells in early apoptosis, dendritic cells reduce their expression of surface MHC and costimulatory molecules, decrease secretion of proinflammatory and T helper (Th)1-driving cytokines, and become weak stimulators of T lymphocytes. Splenic dendritic cells rapidly internalize apoptotic cells from the circulation and the vesicles shed by apoptotic splenocytes bear the entire repertoire of MHC molecules. Thus, systemic administration of donor splenocytes in early apoptosis was one of the first approaches used to deliver donor antigen to host dendritic cells for the purpose of restraining the antidonor T-cell response in transplantation [28] (Fig. 1) . In murine models, intravenous injection of donor splenocytes in early apoptosis, 7 days prior to transplant, prolongs the survival of fully MHC-mismatched cardiac grafts in otherwise untreated recipients. Combination treatment with low-dose blocking anti-CD154 mAb results in long-term survival of most grafts [29, 30] . The effect is donor-specific, dependent on phagocytosis of the apoptotic cells by host splenic conventional dendritic cells, and results from the deletion of indirectly reactive T cells with a consequent relative increase in the percentage of indirectly alloreactive CD4 þ FoxP3 þ Tregs [29] [30] [31] . Interestingly, apoptotic cell therapy also restrains the direct T-cell response, possibly through its immunosuppressive effect on indirectly alloreactive T cells. Owing to its potent regulatory effect on the indirect pathway, therapy with donor apoptotic splenocytes downregulates the production of IgG alloantibody and decreases the development of chronic allograft vasculopathy [30, 31] . A limitation to this approach is that leukocytes in early apoptosis are difficult to preserve and when stored, their progression to late apoptosis diminishes their immunoregulatory potential.
Exosomes released by in-vitro-generated immature dendritic cells have been employed as an alternative vesicle to deliver donor antigen to recipient APCs in situ. Exosomes are nanovesicles (100 nm in size) derived from the endocytic compartment of living cells and released by most, if not all, cell types. Interestingly, APCs secrete exosomes bearing MHC class-I and -II molecules on their membrane, and exosomes injected intravenously are internalized rapidly by splenic conventional dendritic cells. After processing the vesicles, these dendritic cells present exosome MHC-derived peptides to T cells [32] . The composition of the exosomes depends on the stage of maturation/ activation of the parent APC. Exosomes released by immature dendritic cells (immature exosomes) exhibit less T-cell allostimulatory activity and greater capacity to prolong mouse cardiac allograft survival than exosomes secreted by mature dendritic cells (mature exosomes) [33] . Indeed, intravenous injection of exosomes released by donor immature dendritic cells before and after transplant, plus lowdose rapamycin, prevents cardiac allograft rejection and induces donor-specific tolerance in mice [34] . Unlike apoptotic cell-derived vesicles, exosomes are highly stable, but more difficult to produce in sufficient quantities for systemic administration in humans. This may limit their potential therapeutic use in transplantation.
A more specific method to deliver antigen to dendritic cells and to simultaneously promote endocytosis, processing, and presentation of the administered antigen via the endocytic route is to couple the antigen to antibody directed against dendritic cell lectin-like receptors (Fig. 1) þ T-cell responses primarily, whereas in-situ delivery of antigen to CD8 À dendritic cells using 33D1 antibody elicits MHC class-II-restricted CD4 þ T-cell responses [35] . In the absence of dendritic cell maturation stimuli, in-vivo targeting to both dendritic cell subsets in the steady state promotes T-cell tolerance. By contrast, in-situ dendritic cell targeting in combination to agonistic CD40 ligation leads to potent T-cell immunity [35] . Importantly, administration of antigen coupled to CD205 antibody has been shown to induce antigen-specific CD8 þ T-cell deletional tolerance, not only in naive mice [36] , but also in animals with ongoing CD8 þ T-cell immunity [37] . In transplantation, pretreatment of C57BL/6 (B6) mice with a 33D1 antibody conjugated to the H2 K d monomer prevented the development of CD4 þ T-cell indirect alloresponses and IgG alloantibody against partially MHC class-I mismatched skin B6.K d grafts [38] . However, long-term skin graft survival was achieved only when in-situ targeting of dendritic cells was combined with abrogation of the direct CD8 þ T-cell alloresponse by co-administration of a depleting CD8 antibody [38] . These findings suggest that, unlike in autoimmune disorders, downregulation of direct and indirect T-cell responses in transplantation by in-situ targeting of recipient dendritic cells will require the delivery of a broad repertoire of donor antigen/ peptides. The extensive variability in MHC alleles between donors makes this potential therapeutic approach challenging in the transplantation arena.
More recently, mAbs directed against other lectin-like molecules have been tested for delivery of antigen to conventional dendritic cells in vivo. Thus, delivery to dendritic cells of influenza virus hemagglutinin 1 (HA1) or the self-antigen prostatespecific antigen (PSA) fused to a recombinant mAb against the lectin-like dendritic cell-asialoglycoprotein receptor (dendritic cell-ASGPR) generated antigen-specific, interleukin-10-producing suppressive CD4 þ T cells in vitro in humans and in vivo in NHP [39] . These suppressive CD4 þ T cells were FoxP3 À , likely derived from previously polarized Th1 cells, and their regulatory effect was interleukin-10-dependent [39] . Delivery of antigen via dendritic cell-ASGPR antibody promoted interleukin-10 secretion in the target dendritic cell, which was associated with polarization of antigen-specific CD4 þ T cells into interleukin-10-producing cells [39] . In-situ delivery of antigen to conventional dendritic cells through different lectin-like receptors elicits qualitatively and quantitatively different CD4 þ T-cell responses. For instance, targeting of HA1 or PSA to dendritic cells through dendritic cell-ASGPR generated significantly more interleukin-10-secreting CD4 þ T cells than delivery of the same antigen to dendritic cells through other lectinlike receptors, including lectin-like oxidized-lowdensity lipoprotein receptor, Dectin-1, or dendritic cell-specific intercellular adhesion molecule (ICAM)-3-grabbing nonintegrin (dendritic cell-SIGN) [39] . Furthermore, delivery of antigen to dendritic cells via recombinant mAb directed against lectin-like receptors was more efficient at eliciting CD4 þ T-cell responses that loading the corresponding antigenderived peptide pools to dendritic cells [39] . In some cases, the objective of targeting conventional dendritic cells in secondary lymphoid organs with recombinant mAb is to arrest the quiescent status of the dendritic cell, without delivering exogenous antigen, for the antigen is provided by another source (i.e., a transplant). Treatment with the mAb MD-3 directed against domain 2 of human and NHP ICAM-1 molecules prevents the maturation of human myeloid dendritic cells in response to lipopolysaccharide stimulation, without affecting critical functions of ICAM-1, such as adhesion of leukocytes to endothelial cells [40] . Humanized mice rendered diabetic by streptozotocin and injected intravenously with three doses of MD-3 antibody, 9 days prior to transplantation of porcine islets, showed no evidence of xenograft rejection up to the experimental endpoint at 42 days. Ex-vivo analysis indicated that the lack of graft rejection was because of development of xeno-specific T-cell tolerance [40] . In rhesus macaques rendered diabetic by streptozotocin, MD-3 antibody monotherapy before pig islet transplantation promoted pig islet-specific T-cell tolerance, although the islet grafts were quickly rejected. However, long-term survival of the pig xenoislets was achieved when MD-3 antibody therapy was combined with low-dose rapamycin and CD154-blocking antibody [40] .
MODULATION OF ALLOIMMUNITY AND PROLONGATION OF ORGAN TRANSPLANT SURVIVAL BY REGULATORY DENDRITIC CELLS IN NONHUMAN PRIMATES
NHPs are important preclinical models for testing promising new strategies for the promotion of organ transplant tolerance. NHP dendritic cells have been well characterized [41, 42] and shown to modulate alloimmune reactivity in vitro [43, 44] and in vivo [45] . Rhesus macaque monocyte-derived dendritic cells propagated in vitamin (Vit)D3 and interleukin-10 are stably immature, resistant to maturation following potent pro-inflammatory cytokine stimulation, and induce T-cell hyporesponsiveness to alloantigen in vitro [45] . When administered systemically to normal allogeneic rhesus macaques, in combination with the costimulation blocking agent CTLA4-Ig, these DCregs modulate alloimmune reactivity, with resulting T-cell hyporesponsiveness to donor alloantigen, and no detectable circulating IgM or IgG antidonor alloantibody [45] . These rhesus DCregs were examined for their influence on the survival of renal transplants in combination with minimal immunosuppression therapy [21 && ]. Thus, donor-derived DCregs were infused intravenously (3.5-10 Â 10 6 /kg), together with CTLA4-Ig into quiescent, prospective graft recipients, 7 days before renal transplantation. CTLA4-Ig was given for up to 8 weeks and rapamycin, started on day 2, was maintained with tapering of blood levels until full withdrawal at 6 months. Median graft survival time was 39.5 days in control monkeys (no dendritic cell infusion; n ¼ 6) and 113.5 days (P < 0.05) in DCreg-treated recipients (n ¼ 6). No adverse events were associated with the DCreg infusion. Moreover, there was no evidence of induction of host sensitization based on circulating donor-specific alloantibody levels. Significantly, immunologic monitoring revealed regulation of donor-reactive memory CD95
þ T cells and reduced memory/regulatory T-cell ratios in the DCreg-treated monkeys compared with controls ( [21 && ,46] (Fig. 2) . Termination allograft histology showed moderate combined T-cell-mediated and antibody-mediated rejection in both groups.
These findings provide the first evidence of safety and the immunosuppressive efficacy of DCregs in a stringent, preclinical NHP transplant model, and suggest that using DCregs, long-term use of immunosuppressive drugs in transplant recipients could be minimized or even eliminated. The data support further testing of DCregs in organ transplantation together with co-stimulation blockade and mechanistic target of rapamycin inhibition in a calcineurin inhibitor-free and steroid-sparing regimen to reduce host dependence on immunosuppression agents and promote rejection-free allograft survival.
CLINICAL APPLICATION OF REGULATORY DENDRITIC CELLS
Extensive efforts are currently being made to generate DCregs for clinical use. As in murine models, human DCregs have been propagated in vitro from dendritic cell precursors using a wide range of agents, including anti-inflammatory cytokines (in particular interleukin-10), VitD3, neuropeptides, and anti-inflammatory/immunosuppression drugs, such as dexamethasone (Dex) and rapamycin. However, from the perspectives of DCreg tolerogenicity, stability, and capacity for migration to secondary lymphoid tissue, the agent(s) most suitable for clinical application has not been defined. With DCreg therapy, donor monocytes are mobilized by cytokines, isolated by leukapheresis, and differentiated into dendritic cells using granulocyte-macrophage colony-stimulating factor and interleukin-4. DCregs are conditioned with vitamin D3 and interleukin-10 to prevent their maturation and then injected into kidney allograft recipients, 7 days before transplantation. Use of DCregs increases graft survival and inhibits alloantibody production. This is associated with decreased T helper cell proliferation and granzyme B expression, as well as upregulation of negative costimulatory molecules -CTLA4 and PD-1 (B7-H1; CD274) [46] . Reproduced with permission from Macmillan Publishers Limited.
important additional consideration relevant to the improvement of human organ allograft survival is the need to overcome memory CD8 þ T-cell resistance to immunosuppression. In a recent study, Kleijwegt et al. [48 & ] show that (re)activation of human CD8 þ T cells by islet antigen-pulsed monocyte-derived DCregs (VitD3 and Dex-treated) impedes CD8
þ T-cell immunity and depletes memory CD8 þ T cells, an effect ascribed to the absence of costimulation and the secretion of regulatory cytokines (interleukin-10/TGFb).
Despite the challenges associated with translation of DCreg therapy from rodents and NHP to humans, advances such as closed cell culture systems and good manufacturing practice-compliant reagents have allowed strategies for the production of clinical grade DCregs to advance [49] [50] [51] ; reviewed by Raich-Regue et al. [52] . This has led to early (Phase I) clinical trials of DCregs in type 1 diabetes and rheumatoid arthritis [53] [54] [55] , although clinical testing in organ or hematopoietic stem cell transplantation has not yet been reported. There does, however, appear to be adequate justification for moving forward with testing of human DCregs in organ transplantation.
CONCLUSION
Although intensive study in murine models has generated important insight into the mechanisms whereby DCreg therapy or in-situ targeting of tolerogenic dendritic cell promotes long-term allograft survival, as with other forms of regulatory immune cell therapy, the optimal protocol that may achieve this effect in the clinic remains uncertain. Nevertheless, cautious evaluation in phase I/II trials would appear to be justified.
